4.7 Article

Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo

Journal

JOURNAL OF CLINICAL MEDICINE
Volume 8, Issue 6, Pages -

Publisher

MDPI
DOI: 10.3390/jcm8060900

Keywords

regorafenib; osteosarcoma; AKT; ERK

Funding

  1. China Medical University [CMU107-TU-05]
  2. National Yang-Ming University Hospital, Yilan, Taiwan
  3. Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan [RD2019-012, BRD-108009]
  4. Drug Development Center, China Medical University from the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan

Ask authors/readers for more resources

Osteosarcoma is the most common type of bone cancer. Multimodality treatment involving chemotherapy, radiotherapy and surgery is not effective enough to control osteosarcoma. Regorafenib, the oral multi-kinase inhibitor, has been shown to have positive efficacy on disease progression delay in chemotherapy resistant osteosarcoma patients. However anti-cancer effect and mechanism of regorafenib in osteosarcoma is ambiguous. Thus, the aim of this study is to investigate the efficacy and molecular mechanism of regorafenib on osteosarcoma in vitro and in vivo. Human osteosarcomas U-2 OS or MG-63 were treated with regorafenib, miltefosine (protein kinase B (AKT) inhibitor), or PD98059 (mitogen-activated protein/extracellular signal-regulated kinase (MEK) pathway inhibitor) for 24 or 48 h. Cell viability, apoptotic signaling transduction, tumor invasion, expression of tumor progression-associated proteins and tumor growth after regorafenib treatment were assayed by MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, flow cytometry, transwell assay, Western blotting assay and in vivo animal experiment, respectively. In these studies, we also indicated that regorafenib suppressed cell growth by prompting apoptosis of osteosarcoma cells, which is mediated through inactivation of ERK and AKT signaling pathways. After regorafenib treatment, downregulation of related genes in invasion (vascular endothelial growth factor (VEGF) and matrix metallopeptidase 9 (MMP-9)), proliferation (CyclinD1) and anti-apoptosis (X-linked inhibitor of apoptosis protein (XIAP), myeloid cell leukemia-1 (MCL-1), and cellular FLICE (FADD-like IL-1 beta-converting enzyme)-inhibitory protein (C-FLIP)) were found. Moreover, upregulation of caspase-3 and caspase-8 cleavage were also observed. In sum, we suggest that regorafenib has potential to suppress osteosarcoma progression via inactivation of AKT and ERK mediated signaling pathway.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-KB-Mediated Epithelial -Mesenchymal Transition and Metastasis

Yueh-Shan Weng, I-Tsang Chiang, Jai-Jen Tsai, Yu-Chang Liu, Fei-Ting Hsu

Summary: This study suggests that lenvatinib can enhance the anti-hepatocellular carcinoma (HCC) efficacy of radiation therapy (RT) by inhibiting Src/STAT3/NF-KB signaling. The findings reveal the role of targeting Src and its regulation of epithelial-mesenchymal transition (EMT) in increasing the sensitivity of HCC to radiation. Lenvatinib and sorafenib, both multikinase inhibitors, are effective in treating HCC.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Article Medicine, Research & Experimental

Hyperforin Suppresses Oncogenic Kinases and Induces Apoptosis in Colorectal Cancer Cells

Li-Cho Hsu, Chen-Yu Kuo, Fei -Ting Hsu, Hsin Feng Chang, Jing-Jim Ou

Summary: This study found that hyperforin, an active constituent from Hypericum perforatum, suppresses the progression and transformation of colorectal cancer (CRC) by inhibiting the JAK/STAT3, ERK, and AKT signaling pathways, suggesting its therapeutic potential.

IN VIVO (2023)

Article Oncology

Fluoxetine Inhibits STAT3-mediated Survival and Invasion of Osteosarcoma Cells

Wei-Ting Chen, Yuan-Hsin Tsai, Peggy Tan, Fei-Ting Hsu, Hui-Min David Wang, Wei-Chin Lin, Feng-Huei Lin, Ching-Te Wu

Summary: Osteosarcoma is a common bone malignancy with high metastatic characteristics and poor prognosis. Fluoxetine, an anti-depressant, has been shown to have antitumor potential. In this study, fluoxetine was found to induce cytotoxicity and apoptosis in osteosarcoma cells, while also suppressing metastasis and angiogenesis by targeting STAT3.

ANTICANCER RESEARCH (2023)

Article Cell Biology

Inactivation of EGFR/ERK/NF-κB signalling associates with radiosensitizing effect of 18β-glycyrrhetinic acid on progression of hepatocellular carcinoma

Yu-Chang Liu, Cheng Hsun Lin, Kuan-Tin Chen, De-Wei Lai, Fei-Ting Hsu

Summary: Hepatocellular carcinoma (HCC) is a common cancer in Asian population and is relatively insensitive to radiotherapy (RT). Epidermal growth factor receptor (EGFR)-mediated signalling plays a crucial role in HCC treatment efficacy. 18beta-glycyrrhetinic acid (18 beta-GA) has anti-tumor effects, but its ability to sensitize HCC to RT is unclear. This study used RNA data to analyze the relationship between EGFR/ERK/nuclear factor kappa B (NF-kappa B) signalling and RT and found that NF-kappa B activation may lead to RT resistance in HCC. Combining 18 beta-GA with RT enhanced RT efficacy in a Hep3B-bearing animal model. 18 beta-GA acts as a radiosensitizer by inhibiting EGFR-mediated HCC progression and inducing caspase-dependent apoptosis signalling.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2023)

Article Medicine, Research & Experimental

Fluoxetine inactivates STAT3/NF-cB signaling and promotes sensitivity to cisplatin in bladder cancer

Che-Jui Yang, Zhao-Lin Tan, Jr-Di Yang, Fei-Ting Hsu, Chih-Hung Chiang

Summary: Bladder cancer, a common cancer type with poor prognosis, can be divided into MIBC and NMIBC. In this study, the efficacy of fluoxetine, an antidepressant, on BC was investigated. The results showed that fluoxetine induced cytotoxicity, apoptosis, and inhibited invasion and migration in BC cells. Fluoxetine also inactivated the phosphorylation of STAT3 and NF-cB and suppressed their nuclear translocation. In MB49-bearing mice, fluoxetine effectively delayed the progression of BC without inducing toxicity. Overall, fluoxetine targets STAT3 and NF-cB-mediated signaling to inhibit BC progression.

BIOMEDICINE & PHARMACOTHERAPY (2023)

Letter Oncology

In Reply to Yeh et al.

Yueh-Shan Weng, I-Tsang Chiang, Jai-Jen Tsai, Yu-Chang Liu, Fei-Ting Hsu

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Meeting Abstract Oncology

Evaluation of liposome encapsulated sunitinib efficacy and immune modulation on renal cell carcinoma

Po-Fu Yueh, Yuan Chang, Keng-Li Lan, Fei-Ting Hsu

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Fluoxetine mediate radiosensitivity and inhibit metastasis of osteosarcoma cells via RANK/RANKL signaling

Peggy Tan, Jai-Jen Tsai, Fei-Ting Hsu, Yu-Chiang Liu

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Regorafenib enhance PD-L1 expression via ATM activation and evaluate the therapeutic efficacy of combining PD-L1 antibody on bladder cancer

Kai-Jen Pai, I-Tsang Chiang, Fei-Ting Hsu, Jai-Jen Tsai

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Application of AZD2281 combine with radiation therapy in glioblastoma

Tsal-Lan Liao, I-Tsang Chiang, Yuan Chang, Fei-Ting Hsu

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Imipramine induces apoptosis and inhibits metastasis via suppression of EGFR signaling pathway in bladder cancer

Tsai Lin Lo, Jai-Jen Tsai, Fei-Ting Hsu, Yuan Chang

CANCER RESEARCH (2023)

Meeting Abstract Oncology

Hyperforin induces apoptosis and inhibits invasion via inhibiting AKT/NF-kappa B signaling pathway in colorectal cancer cells

Ying-Tzu Chen, I-Tsang Chiang, Yuan Chang, Fei-Ting Hsu

CANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

A Novel Isotope-labeled Small Molecule Probe CC12 for Anti-glioma via Suppressing LYN-mediated Progression and Activating Apoptosis Pathways

Hsu-Shan Huang, I-Tsang Chiang, Bashir Lawal, Yueh-Shan Weng, Long-Bin Jeng, Yu-Cheng Kuo, Yu-Chang Liu, Fei-Ting Hsu

Summary: A newly developed drug called CC12 has been found to effectively penetrate the blood-brain barrier and possess anti-GBM capacity. It initiates apoptotic mechanisms and disrupts LYN/ERK/STAT3/NF-KB-regulated GBM progression, inhibiting tumor growth and metastasis.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2023)

Article Medicine, Research & Experimental

Accessing Apoptosis Induction and Metastasis Inhibition Effect of Magnolol on Triple Negative Breast Cancer In Vitro

Yu-Ching Li, Chui-Na Wong, Fei-Ting Hsu, Jiann-Hwa Chen, Chung-Chi Yang, Heng-Hao Liu, Wei-Lung Chen, Yueh-Shan Weng

Summary: In this study, it was found that magnolol extract from the bark of Magnolia officinalis significantly induced cytotoxicity and apoptosis in TNBC cell lines. It also decreased metastasis and inhibited the EGFR/JAK/STAT3 signaling pathway. Thus, magnolol has the potential to serve as a treatment for TNBC.

IN VIVO (2023)

No Data Available